Ascendis Pharma A/S (ASND) Rose on Positive Trial Results

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned 9.15% (net), compared to a 12.75% return for the Russell 2000 Growth Index. For the year, the fund returned 15.96% (net) compared to 18.66% for the index. In addition, please check the fund’s top five holdings to know its best picks in 2023.

TimesSquare Capital U.S. Small Cap Growth Strategy featured stocks like Ascendis Pharma A/S (NASDAQ:ASND) in the fourth quarter 2023 investor letter. Headquartered in Hellerup, Denmark, Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company. On March 21, 2024, Ascendis Pharma A/S (NASDAQ:ASND) stock closed at $146.19 per share. One-month return of Ascendis Pharma A/S (NASDAQ:ASND) was -8.29%, and its shares gained 39.36% of their value over the last 52 weeks. Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $8.276 billion.

TimesSquare Capital U.S. Small Cap Growth Strategy stated the following regarding Ascendis Pharma A/S (NASDAQ:ASND) in its fourth quarter 2023 investor letter:

“Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that deserve premium pricing, or specialized service providers. We benefited from Ascendis Pharma A/S‘s (NASDAQ:ASND) 34% gain. A biotechnology developer of treatments for rare indications in endocrinology and oncology, Ascendis announced positive results from its Phase 3 trial to treat adult growth hormone deficiency.”

A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor.

Ascendis Pharma A/S (NASDAQ:ASND) is not on our list of 30 Most Popular Stocks Among Hedge Funds. At the end of the fourth quarter, Ascendis Pharma A/S (NASDAQ:ASND) was held by 26 hedge fund portfolios, compared to 22 in the previous quarter, according to our database.

We discussed Ascendis Pharma A/S (NASDAQ:ASND) in another article and shared the list of biggest biotechnology companies in the world. In addition, please check out our hedge fund investor letters Q4 2023 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

• 15 Countries with the Highest Life Expectancy in Africa
• 30 Cities With The Highest Cost of Living
• Top 15 English Speaking Countries in Africa

Disclosure: None. This article is originally published at Insider Monkey.